Motley Fool
Long-term investing & stock picks
Should You Buy Moderna Stock? Why Many Wall Street Analysts Say "No."
By newsfeedback@fool.com (Thomas Niel)
Read original article on Motley FoolModerna (NASDAQ: MRNA) has remained one of the market's hottest biotech stocks. Even as the vaccine maker's shares remain off their 52-week high, hit by news of a breakthrough in using its mRNA technology to create marketable drugs for other diseases and ailments, not just for COVID-19, at around $157 per share, they're still up over sixfold over the past 12 months.
Yet while Moderna may still be sitting pretty right now, analysts remain skeptical whether the stock can hold on to its latest spate of gains.
Image source: Getty Images.
This story was originally published on Motley Fool. DennTech aggregates headlines from top crypto publications to keep traders informed.
Read full article on Motley Fool